Abstract 259: C-reactive Protein Ultrasensitive (hscrp) In Resistant Hypertensive Patients (rhtn) With Left Ventricular Hypertrophy (lvh)
Introduction: Left ventricular hypertrophy (LVH) is an important cardiocerebrovascular risk factor and due to this fact, when present , in hypertensive patients should plan a more elaborate therapeutic treatment. The hsCRP is systemic inflammatory marker associated with increased risk of myocardial infarction and vascular diseases.
Objective: Identify hsCRP as a strong biomarker with correlation with LVH in resistant hypertensive patients (RHTN).
Methodology: A total of 180 patients: 60 RHTN and 60 RHTN with LVH with echocardiographic diagnosis (LVH-RHTN), compared to 60 normal subjects (control), with equal distribution of gender and age. The hs-CPR was measured using nephelometry method.
Results: In LVH-RHTN hsCRP was 3.96 ± 1.11 mg/L and was significantly higher when compared with RHTN, which was 2.20 ± 0.53 mg/L, and with hsCRP 0.56 ± 0.23 in CON (p <0.001). There is a strong correlation between elevated hsCRP and LVH in patients with resistant hypertension, as shown by the Pearson coefficient (r = 0.74).
Conclusion: hsCRP can be considered a strong predictor biomarker in presence of LVH in RHTN.
Author Disclosures: N. Dinamarco: None. M. Dinamarco: None. H. Moreno Jr.: None.
- © 2014 by American Heart Association, Inc.